A Systematic Review of Phase III Clinical Trials of Daratumumab Addition to Standard Care Regimen for Newly Diagnosed Multiple Myeloma

被引：0
|
作者：
Ahmed, Zahoor
Neupane, Karun
Ashraf, Rabia
Khan, Amna
Shahzad, Moazzam
Farooqui, Arafat Ali
Faisal, Muhammad Salman
Nabeel, Shaha
Jamil, Abdur Rehman
Anwer, Faiz
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134895
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022
    Oster, Christoph
    Schmidt, Teresa
    Agkatsev, Sarina
    Lazaridis, Lazaros
    Kleinschnitz, Christoph
    Sure, Ulrich
    Scheffler, Bjorn
    Kebir, Sied
    Glas, Martin
    NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
  • [42] Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials
    Farooqui, Arafat Ali
    Sarfraz, Humaira
    Shah, Zunairah
    Farooqi, Muhammad Saad
    Khan, Maimoona
    Ashraf, Aqsa
    Anjum, Ahmad
    Bin Farooq, Talha
    Shaukat, Tanveer
    Khan, Ali Younas
    Shafqat, Madeeha
    Tariq, Muhammad Junaid
    Anwer, Faiz
    BLOOD, 2019, 134
  • [43] Addition of bevacizumab to the multi-modality standard of care in patients with newly diagnosed glioblastoma: a phase III trial
    Chinot, O.
    Rouge, T. de La Motte
    Moore, N.
    Zeaiter, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 497 - 497
  • [44] Autologous bone marrow transplant in standard-risk newly diagnosed multiple myeloma: A systematic review.
    Kurniawan, Andree
    Priantono, Dimas
    Atmakusuma, Tubagus Djumhana
    Sari, Chandra
    Amelia, Devi Astri Rivera
    Djatnika, Deden
    Nasution, Muhammad Arman
    Siregar, Nia Novianti
    Purlikasari, Nugraheny Prasasti
    Ariyanti, Farieda
    Wisman, Beta Agustia
    Tjhai, Patricia Angel
    Giselvania, Angela
    Wijovi, Felix
    Halim, Devina Adella
    Heriyanto, Rivaldo Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 174 - 174
  • [45] Gene Expression Profiling Predicts Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting
    Claussen, Catherine M.
    Lee, Hans
    Shah, Jatin J.
    Richards, Tiffany
    Shah, Nina
    Patel, Krina
    Bashir, Qaiser
    Parmar, Simrit
    Thomas, Sheeba
    Nieto, Yago
    Qazilbash, Muzaffar H.
    Davis, Richard Eric
    Neelapu, Sattva S.
    Weber, Donna M.
    Orlowski, Robert Z.
    Feng, Lei
    Manasanch, Elisabet E.
    BLOOD, 2016, 128 (22)
  • [46] The Impact Of Immunoparesis On Outcomes Of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review
    Siwakoti, Ashmita
    Khadka, Sukhdev
    Grimshaw, Alyssa
    Giri, Smith
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB78 - AB78
  • [47] Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review
    Khan, Maimoona
    Waheed, Asma
    Ul Jannat, Rida
    Farooqui, Arafat Ali Ali
    Farooqi, Muhammad Saad
    Khan, Ali Younas
    Shafqat, Madeeha
    Ahmad, Muhaddis Ejaz
    Yousaf, Muhammad Abdullah
    Syed, Tariq Iqtidar Sadiq
    Abdullah, Syed Maaz
    Kotapati, Sravanthi
    Riaz, Irbaz
    Anwer, Faiz
    BLOOD, 2019, 134
  • [48] THE HUMANISTIC BURDEN OF MULTIPLE MYELOMA IN NEWLY DIAGNOSED PATIENTS: A SYSTEMATIC LITERATURE REVIEW
    Cizova, D.
    Panjabi, S.
    Abbas, Z.
    Buchanan, J.
    Rose, D.
    Wilke, T.
    VALUE IN HEALTH, 2019, 22 : S527 - S527
  • [49] MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Bhutani, Manisha
    Robinson, Myra
    Foureau, David
    Atrash, Shebli
    Paul, Barry
    Guo, Fei
    Grayson, Jason M.
    Ivanina-Foureau, Anna
    Pineda-Roman, Mauricio
    Varga, Cindy
    Friend, Reed
    Ferreri, Christopher J.
    Begic, Xhevahire
    Norek, Sarah
    Drennan, Tiffany
    Anderson, Michelle B.
    Symanowski, James T.
    Voorhees, Peter M.
    Usmani, Saad Z.
    BLOOD ADVANCES, 2025, 9 (03) : 507 - 519
  • [50] Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
    Kapoor, Prashant
    Gertz, Morie A.
    Laplant, Betsy
    Malave, Gabriella C.
    Wolfe, Eric
    Muchtar, Eli
    Siddiqui, Mustaqeem A.
    Gonsalves, Wilson I.
    Emanuel, Angie R.
    Kourelis, Taxiarchis
    Warsame, Rahma
    Dingli, David
    Buadi, Francis K.
    Hayman, Suzanne R.
    Leung, Nelson
    Hwa, Yi L.
    Hobbs, Miriam A.
    Fonder, Amie
    Dispenzieri, Angela
    Lacy, Martha Q.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD, 2019, 134
12345